Opportunity Information: Apply for RFA HL 12 036
Apply for RFA HL 12 036
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Imaging of the Lung Phase 1 (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Oct 24, 2011 and posted on Oct 24, 2011.
- Applicants must submit their applications by Feb 1, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,800,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) County governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Special district governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Private institutions of higher education State governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Molecular Imaging of the Lung, Phase 1 (R01) funding opportunity (RFA-HL-12-036) was a National Institutes of Health program run by the National Heart, Lung, and Blood Institute (NHLBI) focused on jump-starting new molecular imaging tools specifically designed for lung biology and lung disease. The core idea was to move beyond conventional imaging that mainly shows anatomy or general tissue changes and instead create in vivo imaging reagents and technologies that can visualize specific cells, molecular pathways, or disease-driving processes inside the lung. In practical terms, the FOA sought projects that could produce molecular probes and paired imaging approaches capable of detecting early or subtle biological changes that matter in pulmonary development and in the pathobiology of lung diseases.
Phase I was framed as the development and validation stage. Applicants were expected to (1) identify and justify molecular targets that are clearly relevant to lung health or disease, (2) design and build appropriate molecular probes or imaging reagents aimed at those targets, (3) integrate those probes with innovative imaging methods or platforms, and (4) validate performance in cell-based systems and in vivo animal models. The emphasis was on demonstrating that the probe and imaging approach work as a system: the probe should bind or report on the intended target with meaningful specificity, and the imaging strategy should be capable of detecting and quantifying the signal in living systems, ideally in ways that could later translate toward clinical use.
Although this particular FOA was limited to Phase I, NHLBI signaled that a companion Phase II FOA would be announced later to support studies extending successful approaches into human studies and clinical applications. Importantly, Phase I and Phase II were described as open competitions, meaning Phase I awardees would not automatically advance to Phase II, and new teams could also compete in the later phase. This structure reflects a pipeline approach: build and de-risk the science and technology in animals first, then compete for resources to take the most promising platforms toward clinical translation.
The long-term program goal was broad and clinically driven. NHLBI positioned molecular imaging as a way to improve early detection and diagnosis of lung disease, enable noninvasive monitoring of disease progression and prognosis, and speed progress toward cell-specific drug delivery and therapies. In other words, the envisioned impact was not just better pictures, but better decision-making and better interventions, with imaging serving as a biomarker tool to see disease sooner, track it more accurately over time, and potentially guide targeted treatments.
From an administrative and funding standpoint, this was an R01 research project grant in the health category under CFDA 93.838 (Lung Diseases Research). The opportunity did not require cost sharing or matching. The posting date and creation date were October 24, 2011, with an original and current closing date of February 1, 2012, and an archive date of March 3, 2012. NHLBI estimated total funding at $2,800,000, with an award ceiling listed at $250,000.
Eligibility was intentionally broad and included many types of domestic and non-domestic organizations. Eligible applicants covered federal, state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits both with and without 501(c)(3) status; for-profit organizations (including small businesses and other for-profit entities); public housing authorities and Indian housing authorities; and tribal governments and tribal organizations. The FOA also explicitly included a range of mission-focused or historically underrepresented institutions and organizations such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, and faith-based or community-based organizations. Foreign institutions were also eligible to apply, and foreign components of U.S. organizations were allowed consistent with NIH policy.
For applicants looking for the original full announcement, the FOA referenced an NHLBI/NIH guide page (http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-036.html). The contact information provided for access or technical issues pointed to the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV), particularly for difficulties accessing the announcement or linking to it electronically.
FAQs: Molecular Imaging of the Lung, Phase 1 (R01) - RFA-HL-12-036
What is this funding opportunity?
This opportunity was the Molecular Imaging of the Lung, Phase 1 (R01) funding opportunity announcement (FOA) RFA-HL-12-036. It was a National Institutes of Health (NIH) program run by the National Heart, Lung, and Blood Institute (NHLBI) to jump-start new molecular imaging tools designed specifically for lung biology and lung disease.
What was the main scientific purpose of the FOA?
The FOA aimed to move beyond conventional imaging that mainly shows anatomy or general tissue changes, and instead support the development of in vivo molecular imaging reagents and technologies that can visualize specific cells, molecular pathways, or disease-driving processes inside the lung.
What kinds of outcomes was NHLBI trying to enable long-term?
The long-term program goal was clinically driven: improve early detection and diagnosis of lung disease, enable noninvasive monitoring of disease progression and prognosis, and speed progress toward cell-specific drug delivery and therapies. The intended impact was not just better images, but better decision-making and interventions, with imaging used as a biomarker-like tool.
What does "Phase 1" mean in this program?
Phase I was framed as the development and validation stage. The focus was on building and de-risking the science and technology (including probe design and imaging integration) and demonstrating performance in cell-based systems and in vivo animal models.
What were applicants expected to do in Phase I?
Phase I applications were expected to include: (1) identifying and justifying molecular targets relevant to lung health or disease, (2) designing and building molecular probes or imaging reagents for those targets, (3) integrating probes with innovative imaging methods or platforms, and (4) validating performance in cell-based systems and in vivo animal models.
What is meant by "molecular targets" in this FOA?
Within the context provided, molecular targets are specific cells, molecular pathways, or biological processes that matter in pulmonary development and/or the pathobiology of lung diseases. Applicants were expected to justify that their chosen target was clearly relevant to lung health or disease.
What is meant by "molecular probes" or "imaging reagents" here?
In this FOA, molecular probes or imaging reagents refer to tools designed to bind to, report on, or otherwise indicate the presence or activity of the intended lung-relevant target in vivo, so that an imaging approach can detect and quantify the signal in living systems.
Did the FOA emphasize probes alone, imaging platforms alone, or both together?
Both together. The emphasis was on demonstrating that the probe and the imaging approach work as a system: the probe should bind or report on the intended target with meaningful specificity, and the imaging strategy should be capable of detecting and quantifying the signal in living systems.
What kinds of validation models were expected in Phase I?
The FOA emphasized validation in cell-based systems and in vivo animal models.
Was clinical (human) testing part of this Phase I FOA?
This FOA was limited to Phase I, which focused on development and validation in cell-based systems and animal models. NHLBI indicated a companion Phase II FOA would be announced later to support extension of successful approaches into human studies and clinical applications.
Would Phase I awardees automatically advance to Phase II?
No. Phase I and Phase II were described as open competitions. Phase I awardees would not automatically advance to Phase II, and new teams could also compete in the later phase.
What is the funding mechanism for this opportunity?
The FOA used the NIH R01 research project grant mechanism.
What is the CFDA number and program area?
The opportunity was listed under CFDA 93.838, Lung Diseases Research.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
How much total funding was NHLBI estimating for the program?
NHLBI estimated total funding at $2,800,000.
Was there an award ceiling listed?
Yes. An award ceiling was listed at $250,000.
When was the FOA posted and when did it close?
The posting date and creation date were October 24, 2011. The original and current closing date was February 1, 2012.
When was the opportunity archived?
The archive date was March 3, 2012.
Who ran this FOA?
It was a National Institutes of Health program run by the National Heart, Lung, and Blood Institute (NHLBI).
Who was eligible to apply?
Eligibility was broad and included many types of domestic and non-domestic organizations, including federal, state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations (including small businesses and other for-profit entities); public housing authorities and Indian housing authorities; and tribal governments and tribal organizations.
Were historically underrepresented or mission-focused institutions explicitly included?
Yes. The FOA explicitly included institutions and organizations such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, and faith-based or community-based organizations.
Were foreign institutions eligible?
Yes. Foreign institutions were eligible to apply, and foreign components of U.S. organizations were allowed consistent with NIH policy.
Where can applicants find the original full FOA announcement?
The FOA referenced an NHLBI/NIH guide page at: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-036.html
Who should be contacted for access or technical issues with the announcement link?
The contact provided for difficulties accessing the announcement or linking to it electronically was the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Exploration of Acoustic Environments Natural Sound Field Activities Focused on Diverse and Undeserved Youth
Previous opportunity: Type 1 Diabetes Mouse Resource (UC4)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 036
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 036) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improving Access to Hearing Health Care (SBIR) R43/R44 Apply for RFA DC 12 004 Funding Number: RFA DC 12 004 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Improving Access to Hearing Health Care (STTR) R41/R42 Apply for RFA DC 12 005 Funding Number: RFA DC 12 005 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Service Area Competition Additional Area (SAC AA) (New York, NY) Apply for HRSA 12 167 Funding Number: HRSA 12 167 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Community Nutrition and Health Care Project Apply for USAID GUATEMALA 520 11 000004 Funding Number: USAID GUATEMALA 520 11 000004 Agency: Guatemala USAID Guatemala City Category: Health Funding Amount: $32,000,000 |
| Cardiovascular Research Network (CVRN) Limited Competition (U54) Apply for RFA HL 13 004 Funding Number: RFA HL 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating Psychiatric Disorders (U01) Apply for PAR 12 007 Funding Number: PAR 12 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Revision(s) to the Dominantly Inherited Alzheimer Network (U19) Apply for PAR 12 008 Funding Number: PAR 12 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implications of the Economic Downturn for Health, Wealth, and Work at Older Ages (R01) Apply for PA 12 009 Funding Number: PA 12 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nationwide Program for National and State Background Checks for Direct Patient Access Employees of Long Term Care Facilities and Providers Apply for CMS 1A1 12 002 Funding Number: CMS 1A1 12 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $3,000,000 |
| Support to the Zimbabwe MOH and Child Welfare s Program for PMTCT of HIV. Apply for 674 12 1003 EXPRESSION OF INTEREST Funding Number: 674 12 1003 EXPRESSION OF INTEREST Agency: South Africa USAID Pretoria Category: Health Funding Amount: $60,000,000 |
| HIV Incidence Assays with Improved Specificity (R01) Apply for PA 12 012 Funding Number: PA 12 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Early Independence Awards (DP5) Apply for RFA RM 11 007 Funding Number: RFA RM 11 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Data Coordinating Center for Autism and Other Developmental Disabilities Research and Epidemiologic Studies (U10) Apply for RFA DD 12 001 Funding Number: RFA DD 12 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Area Health Education Centers Apply for HRSA 12 013 Funding Number: HRSA 12 013 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Care Innovation Challenge Apply for CMS 1C1 12 001 Funding Number: CMS 1C1 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $30,000,000 |
| Research Technical Assistance To The Ministry Of Public Health Of Haiti To Support Post Earthquake Reconstruction, Cholera And HIV/AIDS Response Apply for RFA GH 12 003 Funding Number: RFA GH 12 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Evaluation of NIAAAs Alcohol Screening Guide for Children and Adolescents (R01) Apply for RFA AA 12 008 Funding Number: RFA AA 12 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Improved HIV/AIDS Services among Most at Risk Populations (MARPs) in Ukraine Apply for RFA 121 11 000003 Funding Number: RFA 121 11 000003 Agency: Ukraine USAID Kiev Category: Health Funding Amount: $22,000,000 |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO11 110102CONT12 Funding Number: CDC RFA SO11 110102CONT12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO11 110202CONT12 Funding Number: CDC RFA SO11 110202CONT12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 036", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.